Microbix Biosystems Inc. Market Cap ($29.72 Million)
Market Cap & Net Worth: Microbix Biosystems Inc. (MBX)
Microbix Biosystems Inc. market cap. Microbix Biosystems Inc. (TO:MBX) has a market capitalization of $29.72 Million (CA$41.09 Million) as of November 1, 2026. Listed on the TO stock exchange, this Canada-based company holds position #23628 globally and #860 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Microbix Biosystems Inc.'s stock price CA$0.30 by its total outstanding shares 136968656 (136.97 Million). Also see MBX cash flow conversion for how efficiently the company converts equity into cash flow.
Microbix Biosystems Inc. Market Cap History (2015–2026)
Microbix Biosystems Inc. market cap history from 2015 to 2026. Data shows change from $31.71 Million to $29.72 Million (-1.26% CAGR). Check Microbix Biosystems Inc. (MBX) stock price for real-time trading data and today's change.
Microbix Biosystems Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Microbix Biosystems Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Microbix Biosystems Inc. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.23x
Microbix Biosystems Inc.'s market cap is 1.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $25.27 Million | $9.52 Million | $748.41K | 2.65x | 33.76x |
| 2017 | $30.22 Million | $10.19 Million | -$3.78 Million | 2.97x | N/A |
| 2018 | $23.28 Million | $12.51 Million | -$8.62 Million | 1.86x | N/A |
| 2019 | $24.27 Million | $13.41 Million | $31.92K | 1.81x | 760.54x |
| 2020 | $42.11 Million | $10.52 Million | -$6.23 Million | 4.00x | N/A |
| 2021 | $82.24 Million | $18.59 Million | $1.63 Million | 4.42x | 50.45x |
| 2022 | $40.62 Million | $19.08 Million | $1.79 Million | 2.13x | 22.71x |
| 2023 | $38.64 Million | $16.51 Million | -$39.48K | 2.34x | N/A |
| 2024 | $40.62 Million | $25.39 Million | $3.52 Million | 1.60x | 11.54x |
| 2025 | $22.79 Million | $18.59 Million | -$2.25 Million | 1.23x | N/A |
Competitor Companies of MBX by Market Capitalization
Companies near Microbix Biosystems Inc. in the global market cap rankings as of November 1, 2026. Also see how large is Microbix Biosystems Inc.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Microbix Biosystems Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Microbix Biosystems Inc. (2015–2026)
Market capitalization of Microbix Biosystems Inc. from 2015 to today. Between 2015 and today, Microbix Biosystems Inc.'s market cap moved from $31.71 Million to $ 29.72 Million, with a yearly change of -1.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$29.72 Million | +30.43% |
| 2025 | CA$22.79 Million | -43.90% |
| 2024 | CA$40.62 Million | +5.13% |
| 2023 | CA$38.64 Million | -4.88% |
| 2022 | CA$40.62 Million | -50.60% |
| 2021 | CA$82.24 Million | +95.29% |
| 2020 | CA$42.11 Million | +73.47% |
| 2019 | CA$24.27 Million | +4.26% |
| 2018 | CA$23.28 Million | -22.95% |
| 2017 | CA$30.22 Million | +19.61% |
| 2016 | CA$25.27 Million | -20.31% |
| 2015 | CA$31.71 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Microbix Biosystems Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.72 Million USD |
| MoneyControl | $29.72 Million USD |
| MarketWatch | $29.72 Million USD |
| marketcap.company | $29.72 Million USD |
| Reuters | $29.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more